Search results for "SARS-CoV-2 vaccines"

showing 1 items of 1 documents

SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

2022

Abstract Background The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3–6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. Results At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 …

*Pfizer-BioNTech BNT162b2Cancer ResearchCOVID-19 Vaccines*Hematological malignanciesAutologous stem cell transplantationAntibodies ViralBreakthrough SARS-CoV-2 infectionModerna mRNA-1273Cohort StudiesHematological malignancies*Moderna mRNA-1273Correlates of protection*VaccineHumansProspective StudiesVacunacióPfizer-BioNTech BNT162b2Molecular BiologyBNT162 Vaccine*Immunocompromised patients*Correlates of protectionSARS-CoV-2VaccinationHematologic diseasesCOVID-19Hematology*Breakthrough SARS-CoV-2 infectionHematologic DiseasesSARS-CoV-2 vaccinesAllogeneic stem cell transplantationVirusOncologyMalalties hematològiquesImmunocompromised patients*SARS-CoV-2 vaccines*Autologous stem cell transplantation*COVID-19Vaccine*Allogeneic stem cell transplantationJournal of Hematology & Oncology
researchProduct